TORONTO, ONTARIO--(CCNMatthews - Nov. 7, 2005) - Danish approval clears the road to commercial launch across Europe. Orbus Pharma Inc. (TSX:ORB) today announced that it has received notification of regulatory approval for cefuroxime axetil from the Danish Medicines Authority. The product has been approved for use in dosages of 250 and 500 mg tablets. Approval in Denmark allows Orbus to initiate the Mutual Recognition Procedure ("MRP") in pursuit of regulatory approval for the remainder of the European Union countries.
